Shares of Zogenix (NASDAQ:ZGNX) fell 45% after a Food and Drug Administration advisory committee reviewing its extended-release painkiller Zohydro voted 11-2 against the drug. Much of the resistance from the committee focused on potential abuse of the drug, and Zohydro in its current form is not crush-resistant. In this video, Motley Fool health care bureau chief Brenton Flynn tells us why this is such a devastating blow for the company, and what, if anything, in Zogenix's pipeline may save it.
Brenton Flynn, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Covidien Ltd. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.